accelerated closure rates TB-500 : 42-61% increased reepithelialization in full-thickness wounds
But honestly, the short answer doesn't do justice to the science behind it or the potential consequences of getting it wrong
Yes, the human clinical trial evidence is lacking, but there is a silver lining emerging from years of self-experimentation
The peptide has been studied across several distinct use cases in preclinical models, and the dosing rationale differs between them
What Happens When NNMT Is Inhibited
In highly concentrated samples, the biocompatible enhanced viscosity formulation comprises at least about 25%, at least about 35%, at least about 45%, at least about 55%, at least about 65%, at least about 75%, at least about 85%, at least about 90%, at least about 95%, or more by weight of the active agent